CLINICAL BENEFIT OF ADALIMUMAB DOSE ADJUSTMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE IN EXTEND

Jean-Frederic Colombel  1     Paul Rutgeerts  2     William Sandborn  3     Douglas C. Wolf  4     Walter Reinisch  5     Gert Van Assche  2     Samantha Eichner  6     Joel Petersson  7     Anne M. Robinson     Roopal B Thakkar    
1 Icahn School Of Medicine At Mount Sinai, New York, United States
2 University Of Leuven, Leuven, Belgium
3 Ucsd, La Jolla, United States
4 Atlanta Gastroenterology Associates, Atlanta, United States
5 Mcmaster University, Hamilton, Canada
6 Abbvie Inc, North Chicago, United States
7 Abbvie Inc, North

Conference
UEG Week 2014

Citation
United European Gastroenterology Journal; 2014: 2 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing